# Clinical Progress and Prospects of Antibody-drug Conjugates in Advanced NSCLC

## TL;DR

Antibody-drug conjugates (ADCs) are emerging as promising treatments for advanced non-small cell lung cancer, offering potential benefits with high efficacy and low toxicity.

## Contribution

This paper systematically reviews recent advances in ADCs for lung cancer and highlights current challenges in the field.

## Key findings

- ADCs have shown potential as effective and less toxic treatments for advanced NSCLC.
- Despite progress, drug resistance remains a major clinical challenge in NSCLC treatment.
- ADCs are increasingly recognized as a focal point in the development of new lung cancer therapies.

## Abstract

靶向治疗和免疫治疗的进展已显著改善晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）患者的临床结局，并重塑其治疗范式。然而，多数患者终将面临耐药问题，其后线治疗选择有限，疗效不尽如人意，成为当前临床实践的突出难点。近年来，抗体偶联药物（antibody-drug conjugates, ADCs）以其高效低毒的潜在优势，成为该领域关注的焦点。本文系统综述肺癌ADCs治疗领域的研究进展，并探讨当前面临的挑战。

Summary of clinical studies on ADCs in advanced NSCLC